INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Results of Operations and Financial ConditionItem 2.02 –Results of Operations and Financial Condition
On August 14, 2017, the Company issued a press release reporting our financial results for the second quarter ended June 30, 2017. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number |
Description |
|
99.1 |
Press release issued August 14, 2017, reporting financial results for the second quarter ended June 30, 2017 |
INNOVUS PHARMACEUTICALS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE SEC Connect Exhibit 99.1 Innovus Pharmaceuticals Reports a Quarterly Net Revenue Increase of 99.2% and Net Loss Decrease of 74.1% Compared to the Same Period in 2016 FlutiCare™ on Track for Q4 2017 Launch SAN DIEGO,…To view the full exhibit click here
About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.
